Clinical trials: Olanzapine
Breast Cancer
Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile
The objectives of this study are to determine if pharmacogenetic (PG) analysis of an individual enable optimal selection of antiemetic regimen for patients undergoing the first cycle of AC (Adriamycin + Cyclophosphamide) or FEC…
- Trial name
- NCT07455955
- Testing
- Standard antiemetic regimen or Olanzapine antiemetic regimen
- Where
- Hong Kong
- Volunteers
- 60 people
- Sponsor
- Chinese University of Hong Kong
Healthy Controls
Intranasal Insulin and Olanzapine Study in Healthy Volunteers
Antipsychotic (AP) medications are considered to be the gold standard treatment for psychotic disorders including schizophrenia.
- Trial name
- INI/OLA (NCT03741478)
- Testing
- OLANZapine 2.5 MG, Insulin Lispro 100 UNT/ML, Saline
- Where
- 2 sites in Canada
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Cannabinoid Hyperemesis Syndrome
Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department
The aim of the study is to identify which medication (haloperidol or olanzapine) is most effective in treating nausea and abdominal pain associated with cannabinoid hyperemesis using a 10-point visual analog scale with intervals…
- Trial name
- CH2O (NCT07246187)
- Testing
- Olanzapine 10 milligram, Haloperidol
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Mercy Bon Secours Saint Vincent Medical Center
Pediatric Cancer, Nutrition Related Cancer
Pediatric Oncology Nutrition Intervention Trial
Nearly 60% of pediatric patients diagnosed with cancer develop malnutrition caused by a combination of disease burden, side effects of chemotherapy, and the intensity of cancer treatment.
- Conditions
- Pediatric Cancer, Nutrition Related Cancer, Nutrition Aspect of Cancer, Muscle Loss
- Trial name
- POINT (NCT06175273)
- Testing
- Oral Nutrition Supplement, Tube Feed, Cyproheptadine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Corey Hawes
Haloperidol, Advanced Cancer
HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial
1. Background and Clinical Need: Delirium is common at the end of life and is challenging to control. There is a clinical need to study the benefits of commonly used drugs like Haloperidol and Olanzapine in the management of…
- Conditions
- Haloperidol, Advanced Cancer, Hyperactive Delirium, Olanzapine
- Trial name
- NCT04833023
- Testing
- Haldol 2mg/ml oral solution, Olanzapine Actavis 5mg orodispersible tablet
- Where
- 3 sites in Singapore
- Volunteers
- 22 people
- Sponsor
- Tan Tock Seng Hospital
Insulin Resistance, Menstrual Cycle
Effects of Antipsychotics on Brain Insulin Action in Females
Females treated with antipsychotics have higher rates of comorbid metabolic syndrome than males. Despite this, females have historically been excluded from many mechanistic studies due to confounding effects of menstrual cycles.
- Conditions
- Insulin Resistance, Menstrual Cycle, Type 2 Diabetes, Antipsychotics
- Trial name
- NCT06251635
- Testing
- Olanzapine 2.5Mg Oral Tablet, Insulin Lispro 100 UNT/ML, Saline
- Where
- Canada
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Vomiting in Infants and/or Children, Nausea
RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy
Chemotherapy-induced nausea and vomiting (CINV) are among the most bothersome symptoms during cancer treatment according to children and their parents.
- Conditions
- Vomiting in Infants and/or Children, Nausea, Hematopoietic System--Cancer, Oncology
- Trial name
- NCT03118986
- Testing
- Olanzapine
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 161 people
- Sponsor
- The Hospital for Sick Children
Solid Tumor Cancer
Fosrolapitant and Palonosetron for Highly Emetogenic ADC-Induced Nausea and Vomiting in Solid Tumors
This study aims to evaluate the efficacy and safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in preventing nausea and vomiting induced by highly emetogenic antibody-drug conjugate (ADC) therapy in patients…
- Trial name
- NCT07841210
- Testing
- Fosrolapitant and Palonosetron; Dexamethasone; Olanzapine, Fosrolapitant and Palonosetron; Dexamethasone
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Tinnitus, Tinnitus, Subjective
Treatment of Tinnitus With Olanzapine
This research aims to evaluate the effects of the drug olanzapine on the discomfort caused by tinnitus according to each patient's personality traits.
- Trial name
- OLANZAP_TIN (NCT07190482)
- Testing
- Olanzapine 5 Mg ORAL TABLET
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- University of Sao Paulo
Schizophrenia
A Study for Participants With Schizophrenia
The purpose of this study is to test the hypothesis that 1 or more dose levels of LY2140023 given orally to participants with schizophrenia twice daily for 4 weeks will have significantly greater effect than placebo.
- Trial name
- NCT00520923
- Testing
- LY2140023, Olanzapine
- Where
- 35 sites in Argentina, Austria and 7 more
- Volunteers
- 669 people
- Sponsor
- Denovo Biopharma LLC
Schizophrenia
A Long-Term, Open-Label, Study on Schizophrenia
The primary purpose of the study is to help answer the following research questions: How LY 2140023 can be tolerated by patients with Schizophrenia compared to standard of care treatment in 52 weeks time period.
- Trial name
- NCT01129674
- Testing
- LY2140023, Olanzapine, Aripiprazole
- Where
- 81 sites in United States, Croatia and 7 more
- Volunteers
- 560 people
- Sponsor
- Denovo Biopharma LLC
Misuse, Opioid
Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial
To learn about the effectiveness of taking the antipsychotic medication olanzapine to help lower opioid craving.
- Trial name
- NCT06200181
- Testing
- Olanzapine
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumours, Olanzapine
Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis
Olanzapine is an effective antiemetic agent for preventing highly emetogenic regimens-induced nausea and vomiting (HER-INV) in patients receiving highly emetogenic regimens (HER).
- Conditions
- Solid Tumours, Olanzapine, Nausea and Vomiting
- Trial name
- NCT07403370
- Testing
- Olanzapine (dose comparison: 2.5 mg, 5 mg, 10 mg)
- Where
- China
- Volunteers
- 2,493 people
- Sponsor
- Shandong Cancer Hospital and Institute
Hyperglycemia, Hyperlipidemia
Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone
Primary Aim: To test the acute effects of olanzapine or ziprasidone administration, in comparison to placebo, on insulin sensitivity in antipsychotic-naïve healthy young men, measured as whole-body dextrose infusion rates…
- Trial name
- NCT00910988
- Testing
- Olanzapine, Ziprasidone
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Chemotherapy-induced Nausea and Vomiting
Steroid-sparing Therapy (Olanzapine) Versus Dexamethasone-based Therapy for Chemotherapy-induced Nausea and Vomiting
The purpose of this research is to compare two drugs that are routinely used as standard of care for treating nausea and vomiting caused by chemotherapy.
- Trial name
- NCT05590923
- Testing
- OLA group: Olanzapine, DEX group: Dexamethasone
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- The Guthrie Clinic
Gastric Adenocarcinoma, Gastric Cancer
GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer
This is a single-center, randomized, open-label clinical trial designed to evaluate the impact of low-dose olanzapine on weight loss, appetite, and nutritional outcomes in patients with gastric cancer receiving neoadjuvant…
- Trial name
- NCT07581405
- Testing
- Neoadjuvant chemotherapy, Olanzapine
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Illinois at Chicago
Cancer-Associated Anorexia, Head and Neck Squamous Cell Carcinoma
Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial
This phase II trial compares the effect of adding olanzapine to standard of care symptom management for nausea to standard of care alone in managing an abnormal loss of the appetite for food (anorexia) in patients treated with…
- Conditions
- Cancer-Associated Anorexia, Head and Neck Squamous Cell Carcinoma, Neck Squamous Cell Carcinoma of Unknown Primary
- Trial name
- NCT06995508
- Testing
- Best Practice, Olanzapine, Questionnaire Administration
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Roswell Park Cancer Institute
Schizophrenia, Bipolar I Disorder
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine
- Trial name
- NCT05303064
- Testing
- OLZ/SAM, Olanzapine
- Where
- 47 sites in United States, Argentina and 3 more
- Volunteers
- 220 people
- Sponsor
- Alkermes, Inc.
Olanzapine, Breast Cancer
Olanzapine Based Dexamethasone-sparing Regimen for Breast Cancer Patients With Metabolic-risk Factors
The aim of THE STUDY to determine whether an olanzapine-based dexamethasone-sparing antiemetic regimen is non-inferior to the standard dexamethasone-containing regimen in preventing delayed-phase Chemotherapy-induced nausea and…
- Conditions
- Olanzapine, Breast Cancer, Dexamethasone
- Trial name
- NCT07743827
- Testing
- Pantoprazole, olanzapine, Dexamethasone
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Alexandria University
Bipolar 1 Disorder, Schizophrenia Disorder
An Expanded Access Program (EAP) for OLZ/SAM in Pediatric Participants With Schizophrenia or Bipolar I Disorder (ALKS 3831-315)
To provide continued access to OLZ/SAM for pediatric participants with schizophrenia or bipolar I disorder who have completed participation in the ALKS 3831-A313 long-term safety extension study.
- Trial name
- NCT07744113
- Testing
- OLZ/SAM
- Where
- United States
- Sponsor
- Alkermes, Inc.